$2.5M
6.0x
Subscribe Free
Read the full deal writeup
Sign up for a free Accredited account to read the editorial writeup, financials, and broker contact for this deal.
Get Free AccessFull Editorial Writeup
Founded in 2004, this pharmacy has built a strong reputation and a loyal customer base. With contracts with all major insurance carriers and a 340B license, this business offers a seamless transition for an experienced operator or investor looking to enter or expand within the specialty pharmacy sector. The...
Why we like it
- 340B license creates structural cost advantages through discounted drug purchasing that can't be easily replicated. This federal program designation provides permanent margin expansion compared to standard retail pharmacies, creating a meaningful competitive moat.
- Insurance contracts with all major carriers provide revenue stability and reduce customer acquisition friction. Specialty pharmacy typically involves higher-margin, recurring prescription fulfillment with strong patient retention due to chronic conditions requiring ongoing treatment.
- Healthcare tailwinds favor specialty pharmacies as drug complexity increases and aging demographics drive prescription volume growth. The shift toward specialty medications for cancer, autoimmune, and rare diseases creates a growing addressable market with higher average prescription values.
- At 6x cash flow with $2.5M in earnings, the multiple suggests reasonable valuation for a cash-generative healthcare asset. The 22-year operating history demonstrates business durability through multiple economic cycles and regulatory changes.
How to improve it
- Audit 340B compliance and maximize program utilization by ensuring all eligible patients are captured. Many specialty pharmacies underutilize their 340B savings opportunities, leaving significant margin expansion on the table through better patient identification and claims processing.
- Implement automated prescription management and patient adherence programs to reduce labor costs and improve outcomes. Technology upgrades in specialty pharmacy often pay for themselves within 12 months through reduced manual processing and improved fill rates.
- Expand clinical services like medication therapy management and specialized compounding if not already offered. These higher-margin services differentiate from mail-order competitors and create additional revenue streams while improving patient outcomes.
- Negotiate better terms with existing insurance contracts and pursue additional payer relationships. A 22-year track record provides leverage for improved reimbursement rates, especially with regional insurers seeking local specialty pharmacy partners.
- Evaluate acquisition opportunities for additional 340B-eligible locations or independent pharmacies to create economies of scale. The specialty pharmacy industry is consolidating, creating opportunities to acquire smaller players at attractive multiples.
Diligence notes
- Verify 340B compliance status and review recent audit history, as violations can result in program termination and significant financial penalties. The Office of Inspector General has increased scrutiny of 340B programs, making compliance documentation critical for valuation.
- Analyze prescription mix and payer concentration to understand revenue stability and reimbursement trends. Specialty drugs face ongoing pricing pressure, and understanding which therapeutic categories drive profitability is essential for forecasting.
- Review insurance contract terms and renewal dates to assess reimbursement security and identify potential risks. Some contracts include claw-back provisions or performance requirements that could impact future cash flows.
- Examine staffing structure and regulatory compliance costs, as specialty pharmacies require licensed pharmacists and face stricter regulatory oversight than retail operations. Labor costs and compliance burden can significantly impact margins if not properly managed.